ChitogenX Inc. (CHGX.CN)
CAD 0.01
(0.0%)
CAD 0.01
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -2.69 Million CAD | 43.26% |
| 2022 | -4.65 Million CAD | -43.88% |
| 2021 | -3.18 Million CAD | -16.28% |
| 2020 | -2.54 Million CAD | -37.43% |
| 2019 | -2.21 Million CAD | 6.8% |
| 2018 | -2.21 Million CAD | -25.66% |
| 2017 | -1.76 Million CAD | -66.18% |
| 2016 | - CAD | -60.2% |
| 2015 | -919.92 Thousand CAD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 14 Thousand CAD | 105.15% |
| 2024 Q2 | -118 Thousand CAD | -942.86% |
| 2023 Q3 | -346 Thousand CAD | 39.72% |
| 2023 Q1 | -1.04 Million CAD | 9.9% |
| 2023 Q2 | -574 Thousand CAD | 45.18% |
| 2023 Q4 | -734 Thousand CAD | -112.14% |
| 2023 FY | - CAD | 41.28% |
| 2022 Q2 | -1.1 Million CAD | 13.66% |
| 2022 FY | - CAD | -43.88% |
| 2022 Q4 | -1.16 Million CAD | 3.09% |
| 2022 Q3 | -1.19 Million CAD | -8.41% |
| 2022 Q1 | -1.28 Million CAD | -44.75% |
| 2021 Q4 | -885 Thousand CAD | 9.04% |
| 2021 Q1 | -888 Thousand CAD | 6.72% |
| 2021 Q2 | -554 Thousand CAD | 37.61% |
| 2021 Q3 | -973 Thousand CAD | -75.63% |
| 2021 FY | - CAD | -16.28% |
| 2020 Q4 | -952 Thousand CAD | -55.81% |
| 2020 FY | - CAD | -37.43% |
| 2020 Q3 | -611 Thousand CAD | -47.94% |
| 2020 Q1 | -862 Thousand CAD | -218.08% |
| 2020 Q2 | -413 Thousand CAD | 52.09% |
| 2019 FY | - CAD | 6.8% |
| 2019 Q4 | -271 Thousand CAD | 55.57% |
| 2019 Q3 | -610 Thousand CAD | -7.21% |
| 2019 Q2 | -569 Thousand CAD | -15.18% |
| 2019 Q1 | -494 Thousand CAD | 25.72% |
| 2018 Q2 | -437.06 Thousand CAD | -9.51% |
| 2018 Q1 | -399.12 Thousand CAD | 29.77% |
| 2018 Q3 | -714.52 Thousand CAD | -63.48% |
| 2018 Q4 | -665.02 Thousand CAD | 6.93% |
| 2018 FY | - CAD | -25.66% |
| 2017 FY | - CAD | -66.18% |
| 2017 Q1 | -174.85 Thousand CAD | -7.46% |
| 2017 Q2 | -339.25 Thousand CAD | -94.03% |
| 2017 Q3 | -587.69 Thousand CAD | -73.23% |
| 2017 Q4 | -568.27 Thousand CAD | 3.3% |
| 2016 Q2 | -348.87 Thousand CAD | -29.1% |
| 2016 FY | - CAD | -60.2% |
| 2016 Q4 | -162.71 Thousand CAD | 41.72% |
| 2016 Q1 | -270.24 Thousand CAD | 59.25% |
| 2016 Q3 | -279.21 Thousand CAD | 19.97% |
| 2015 Q2 | -53.58 Thousand CAD | -46.68% |
| 2015 FY | - CAD | 0.0% |
| 2015 Q4 | -663.12 Thousand CAD | -297.83% |
| 2015 Q1 | -36.53 Thousand CAD | 0.0% |
| 2015 Q3 | -166.68 Thousand CAD | -211.07% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | -4.98 Million CAD | 45.919% |
| Asep Medical Holdings Inc | -8.13 Million CAD | 66.888% |
| BetterLife Pharma Inc. | -3.19 Million CAD | 15.587% |
| BioVaxys Technology Corp. | -7.68 Million CAD | 64.955% |
| Rapid Dose Therapeutics Corp. | -3.02 Million CAD | 10.934% |
| Defence Therapeutics Inc. | -12.67 Million CAD | 78.747% |
| Entheon Biomedical Corp. | 13.99 Thousand CAD | 19352.483% |
| Gemina Laboratories Ltd. | -5.17 Million CAD | 47.95% |
| Glow Lifetech Corp. | -1.26 Million CAD | -113.295% |
| Lexston Life Sciences Corp. | -648.32 Thousand CAD | -315.533% |
| Pharmala Biotech Holdings Inc. | -710.18 Thousand CAD | -279.338% |
| Doseology Sciences Inc. | -319.47 Thousand CAD | -743.251% |
| MYND Life Sciences Inc. | -1.82 Million CAD | -47.601% |
| Nova Mentis Life Science Corp. | -1.2 Million CAD | -124.071% |
| PharmaTher Holdings Ltd. | -3.04 Million CAD | 11.48% |
| PreveCeutical Medical Inc. | -955.08 Thousand CAD | -182.068% |
| Telescope Innovations Corp. | -5.49 Million CAD | 50.933% |